سعر نيريسيد سي كريم 10جم 2022

Topical cream (10 g tube) by CID, Egypt, combining diflucortolone valerate 0.1% (potent corticosteroid) with chlorquinaldol 1% (antibacterial/antifungal quinoline antiseptic).

• Initial intermittent treatment of bacterially and/or mycotically infected skin diseases with predominant inflammation where a cream is indicated: eczemas with bacterial/mycotic superinfection (nummular, seborrhoeic, dyshidrotic, varicose eczema not applied directly to leg ulcers), pyoderma (folliculitis, impetigo), erythrasma and dermatomycoses (tinea, candidiasis, pityriasis versicolor); also to prevent such infections in inflammatory and allergic skin diseases.CID EXPORT product gallery (cid.do.am)

• With large areas (about 10% or more) and/or long use (more than 4 weeks): skin atrophy, telangiectasia, striae, acneiform changes, perioral dermatitis, hypertrichosis and systemic corticosteroid effects; rarely allergic skin reactions. Effects in neonates cannot be excluded after extensive or prolonged maternal use during pregnancy or lactation.Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Common local reactions: burning, pruritus, erythema and irritation. With large areas (10% or more) or long use (more than 4 weeks), especially with occlusion: skin atrophy, telangiectasia, striae, acneiform changes, perioral dermatitis, hypertrichosis and systemic corticosteroid effects; rarely allergic skin reactions.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Tuberculous or syphilitic processes in the treated area; viral diseases (e.g. vaccinia, chickenpox, shingles). As a general rule not to be applied in the first trimester of pregnancy; application to large areas or for prolonged periods must be avoided.Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Rosacea and perioral dermatitis; acne vulgaris; undiagnosed perianal and genital pruritus; napkin eruptions; viral infections; primary bacterial or fungal skin infections; secondary infections without appropriate anti-infective therapy; post-vaccination skin reactions in the treated area; ophthalmic conditions; hypersensitivity to the active substance or excipients.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Avoid contact with the eyes when applied to the face; must not be applied to the face if rosacea or perioral dermatitis is present.Per the manufacturer · CID EXPORT product gallery (cid.do.am)
• Adrenal suppression can occur even without occlusion; systemic absorption increases with occlusion, large areas or prolonged use.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)
• Use in psoriasis may be hazardous (rebound relapse, generalised pustular psoriasis, local and systemic toxicity); careful supervision is needed.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Inadequate evidence of safety in human pregnancy; topical corticosteroids in pregnant animals can cause foetal abnormalities (e.g. cleft palate, intra-uterine growth retardation); application to large areas or for prolonged periods must be avoided.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)
• Side effects in neonates cannot be excluded after extensive or prolonged maternal use during pregnancy or lactation; nursing mothers should not apply it to the breasts.General active-ingredient information · MHRA Products (UK Medicines and Healthcare products Regulatory Agency)

• Diflucortolone valerate: Suppresses cutaneous inflammation and alleviates pruritus/burning in inflammatory dermatoses.
• Chlorquinaldol: Inhibits the growth of bacteria, yeasts, dermatophytes and moulds (manufacturer product page).